


We deliver optimal care to people with chronic diseases living at home and using your product – Happy@Home


- Increased adherence through individual patient support and order reminders
- Market access-support KVV Art. 71 a–c
- In depth market understanding through reports and individual surveys
- In depth understanding of patients through targeted surveys

Increase patient's independence and therapy success



- We offer a highly specialized team of nurses (intensive care, emergency, anaesthesiology, MS Nurse PRO certification)
- Coordination between care providers (e.g. physicians, health insurers, Spitex, hospital)
- Infusions in private practices
- Infusions at the patient's home
- Individual contact person for the duration of a therapy
- Regular contacts with patients through home visits, by video and by telephone
- Regular updates of supervising physician
- 24/7 call service for home care patients


Increased adherence through home care and order reminder service



- Already basic counselling at home or by video and telephone can have a significant impact on the health of your patients¹⁻⁴
- A study performed in Switzerland in collaboration with the University Hospital Bern confirms already existing data^{2,3,4}
Patient on home care remain significantly longer on therapy (265 vs. 152 days)¹
The study compared patients with hepatocellular carcinoma¹ on sorafenib with and without home care
- SMS, e-mail or telephone order reminders significantly increased adherence*

Kaplan-Meier curve of the duration of treatment of home care vs. non-home care patients.⁵

Market Access: 20 years of experience in the introduction of new products into the market.



- Early access program
- KVV Art. 71 a–c support
- Import on a named patient basis
- Administrative support for inquiries and invoices concerning Article 71 a–c.
- Support of physicians for obtaining insurer's reimbursement approval
- Delivery of medication to a Swiss address (including holiday home)
- For additional product monitoring, we offer advanced pharmacovigilance services

Detailed reports strictly fulfilling all requirements of the Swiss data protection law



- Graphic preparation & interpretation of presentations
- Regular sales- and therapy reports, including time based therapy analysis
- Reports for patient support programs (PSP)
- Analysis of Patient-Reported Outcome Measures (PROMs) & Reported Experience Measures (PREMs)

Patient surveys



- Insights into the patient journey through structured, targeted surveys in our extensive patient pool



Based on a representative survey covering >1'000 of our patients we are proud to say: our patients are exceedingly happy with MediService!

¹ Moser, M., Radu, I.-P. & Dufour, J.-F. Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH Open, 7 (2021).
² Wu, J. Y. et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 333, 522, doi:10.1136/bmj.38905.447118.2F (2006).
³ Stuurman-Bleze, A. G., Hiddink, E. G., van Boven, J. F. & Vegter, S. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int 25, 1807-1812, doi:10.1007/s00198-014-2659-8 (2014).
⁴ Mäurer, M. et al. in 1st Congress of the European Academy of Neurology 1 (Berlin, 2015).
⁵ Moser, M. Home Care in patients with hepatocellular carcinoma treated with sorafenib: Analysis of the Bern HCC Cohort - Prospective Cohort Study Master thesis, University of Bern, (2019).
 * χ^2 Test: Significantly more frequent timely reorders.